Health Condition 1: I251- Atherosclerotic heart disease of native coronary artery
Conditions
Interventions
Intervention1: Beta Nicotinamide Mononucleotide: Tablet beta NMN 500 mg once a day orally for 180 days
Control Intervention1: Lactose: Tablet Lactose 500mg once a day orally for 180 days
Sponsors
Indian Council of Medical Research (ICMR)
Eligibility
Inclusion criteria
Inclusion criteria: Adult patients with suspected Coronary artery disease with stable typical or atypical symptoms suspicious for coronary artery disease like chest pain chest tightness chest burning shoulder pain palpitations jaw pain or non chest pain symptoms such as dyspnea or worsening effort tolerance and who are considered to be at very low to high risk of coronary artery disease based on initial clinical assessment Willing to take beta NMN 500 mg per day for six months Willing to have blood drawn three times at baseline three months and six months
Exclusion criteria
Exclusion criteria: Patients being evaluated for other Cardiac diseases like valvular disease etiology of cardiomyopathy Patients with unstable angina who have elevated serum cardiac biomarkers ECG changes etc Patients with NSTE ACS NSTEMI and STEMI Patients with liver disease renal disease joint pain hypothyroid or hyperthyroid disease cerebrovascular disease anemia and chronic obstructive lung disease Individuals unwilling to undergo investigations or provide consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Improvement in the quality of life DNA Methylation and NAD concentrationTimepoint: Day 0 Day 90 Day 180 | — |
Secondary
| Measure | Time frame |
|---|---|
| Improvement in the six minute walking test and relative leukocyte telomere lengthTimepoint: Day 0 Day 90 Day 180 | — |
Countries
India
Contacts
Public ContactDr Melvin George
SRM Medical College Hospital and Research Centre, SRM UNIVERSITY
Outcome results
None listed